Recommendation of the President – Abrysvo (respiratory syncytial virus vaccine bivalent, recombinant)

On 13 November 2024, the President of the Agency for Health Technology Assessment and Tariff System issued recommendation No. 125/2024 on the appraisal of Abrysvo (Respiratory syncytial virus vaccine bivalent, recombinant) vaccine, bivalent, recombinant) for the indication: passive protection against lower respiratory tract diseases caused by syncytial respiratory virus (RSV) in infants from birth to 6 months of age after maternal vaccination during pregnancy

Publication in Public Information Bulletin (BIP) >>